Accession Number: | 0001209191-20-045095 |
Date: | 2020-08-03 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
ALTSHULER DAVID
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-08-03 | M | 2,330 | a | $86.52 | 31,232 | direct | ||
COMMON STOCK | 2020-08-03 | S | 458 | d | $276.84 | 30,774 | direct | ||
COMMON STOCK | 2020-08-03 | S | 1,167 | d | $278.14 | 29,607 | direct | ||
COMMON STOCK | 2020-08-03 | S | 605 | d | $279.19 | 29,002 | direct | ||
COMMON STOCK | 2020-08-03 | S | 100 | d | $279.98 | 28,902 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 86.52 | 2020-08-03 | deemed execution date | M | 2,330 (d) | 2027-02-02 | common stock 2,330 | $86.52 | 4,660 | direct |
ID | footnote |
---|---|
f1 | transaction made pursuant to dr. altshuler's company approved trading plan under rule 10b5-1. |
f2 | open market sales reported on this line occurred at a weighted average price of $276.84 (range $276.62 to $277.20). |
f3 | dr. altshuler undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f4 | open market sales reported on this line occurred at a weighted average price of $278.14 (range $277.79 to $278.65). |
f5 | open market sales reported on this line occurred at a weighted average price of $279.19 (range $278.86 to $279.62). |
f6 | the option vests in 16 quarterly installments from 02/03/2017. |